LivaNova is a London-based medical device company that develops and manufactures products for use in epilepsy treatment and interventional cardiology. With the divestiture of the company's cardiac rhythm management division now complete, the firm reports in two primary segments: cardiac surgery (roughly 60% of 2018 sales) and neuromodulation (40%). The company's revenue mix shifted further toward the U.S. after the divestiture, with roughly 50% of total sales derived from the U.S., 20% from Europe, and 30% from the rest of the world.
